Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Scientific Officer

Chief Financial Officer

Chief Operating Officer

Chief Business Officer

President and CEO

Executive Chairman

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-09	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-09	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-08-15	Premium	sold	Premium	Premium	Premium	-
2022-09-23	Premium	sold	Premium	Premium	Premium	-
2022-09-08	Premium	acquired	Premium	Premium	Premium	-
2022-02-23	Premium	acquired	Premium	Premium	Premium	-
2021-12-14	Premium	acquired	Premium	Premium	Premium	-
2021-12-14	Premium	sold	Premium	Premium	Premium	-
2021-06-21	Premium	acquired	Premium	Premium	Premium	-
2021-06-21	Premium	acquired	Premium	Premium	Premium	-
2021-06-21	Premium	acquired	Premium	Premium	Premium	Executive Chairman
2021-06-21	Premium	acquired	Premium	Premium	Premium	-
2021-06-21	Premium	acquired	Premium	Premium	Premium	-
2021-06-21	Premium	bought	Premium	Premium	Premium	-
2021-06-21	Premium	acquired	Premium	Premium	Premium	-

LYEL - Lyell Immunopharma, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for LYEL